Results 191 to 200 of about 32,100 (296)

Clinical Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy for Triple‐Negative Breast Cancer and Tumor Immune Microenvironment Analysis: A Prospective‐Retrospective Cohort Study

MedComm, Volume 7, Issue 9, September 2026.
Cohort Study Design:Between January 2019 and July 2023, 276 stage II‐III TNBC patients were enrolled in this study, including 56 in the NIC cohort and 220 in the NAC cohort. Due to 17 cases of ineligible criteria, 5 with withdrawal of informed consent, 198 patients in the NAC cohort completed NAC and underwent surgical resection.
Yongsheng Wang, Pengfei Qiu, Yuechen Wang, Xingchen Meng, Jiaxin Zhang, Haiqiang Liu, Zhiqiang Shi, Zhaopeng Zhang, Xiao Sun, Chunjian Wang, Xiangjing Meng, Chunhui Zheng   +11 more
wiley   +1 more source

Long-term Subclinical Cardiotoxicity of Modern Cardiotoxic Treatment Protocols in Childhood Cancer Survivors Assessed by Cardiovascular Magnetic Resonance T1 Mapping and Circulatory Biomarkers. [PDF]

Cardiovasc Toxicol
Panovský R, Tomandlová M, Mojica-Pisciotti ML, Kepák T, Máchal J, Feitová V, Frič J, Hortová-Kohoutková M, Holeček T, Tomandl J, Opatřil L, Kincl V.   +11 more
europepmc   +1 more source

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 5, Page 625-634, September 2026.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source

Protecting the Heart Against Anthracyclines: The Elusive Search for the Optimal Cardiomyocyte Model. [PDF]

JACC Basic Transl Sci
Narvaez-Paliza JM, Asnani A.
europepmc   +1 more source

Eccrine Squamous Syringometaplasia Mimicking Acute Cutaneous GVHD in a Pediatric HSCT Recipient: Case Report and Brief Review of the Indexed Literature

Journal of Cutaneous Pathology, Volume 53, Issue 9, Page 792-802, September 2026.
ABSTRACT Eccrine squamous syringometaplasia (ESS) is an uncommon reactive alteration of eccrine ducts, most often reported in oncologic and transplant settings, where it may clinically mimic acute cutaneous graft‐versus‐host disease (GVHD). We describe a 3‐year‐old boy with chronic granulomatous disease who developed a diffuse erythematous eruption 6 ...
Benedetta Galli, Cecilia Catapano, Iacopo Ghini, Mariateresa Rossi, Marina Venturini, Valeria Boccaletti   +5 more
wiley   +1 more source

Exploring the Pleiotropic Cardioprotective Effects of GLP-1 Receptor Agonists in Preventing Anthracycline-Induced Cardiotoxicity: A Theoretical Proposal for Future Research. [PDF]

Medicines (Basel)
Repp ML, Chinyere IR, Teran S, Bast J, Kondapalli L.   +4 more
europepmc   +1 more source

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 532-544, September 2026.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source

Association of early dexrazoxane with reduced cardiotoxicity risk in sarcoma patients treated with anthracycline chemotherapy. [PDF]

Oncologist
Jang KH, Wallins JS, Lin IH, Movva S, Tap WD, Liu JE, Yu AF.   +6 more
europepmc   +1 more source

P53 Competitively Binds P300 to Suppress HIF‐1α/TFRC‐Mediated Ferroptosis and Promote Doxorubicin Resistance in Breast Cancer

The FASEB Journal, Volume 40, Issue 16, 31 August 2026.
Upregulated P53 competitively binds P300, reducing its availability to HIF‐1α and thereby decreasing HIF‐1α/P300 co‐occupancy and transcriptional activation at the TFRC promoter. The resulting reduction in TFRC‐dependent iron uptake weakens Fenton reactions, lipid peroxidation, and ferroptosis, ultimately promoting doxorubicin resistance in breast ...
Xiaojie Yu, Longdi Yao, Shuchun Zhang, Xiao Huang, An Xu, Deyuan Fu   +5 more
wiley   +1 more source